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Platelet Glycoprotein IIb/IIIa Receptor Inhibition in
Non–ST-Elevation Acute Coronary Syndromes
Early Benefit During Medical Treatment Only, With Additional Protection
During Percutaneous Coronary Intervention
Eric Boersma, PhD; K. Martijn Akkerhuis, MD; Pierre The´roux, MD, PhD;
Robert M. Califf, MD, PhD; Eric J. Topol, MD, PhD; Maarten L. Simoons, MD, PhD
Background—Glycoprotein (GP) IIb/IIIa receptor blockers prevent life-threatening cardiac complications in patients with
acute coronary syndromes without ST-segment elevation and protect against thrombotic complications associated with
percutaneous coronary interventions (PCIs). The question arises as to whether these 2 beneficial effects are independent
and additive.
Methods and Results—We analyzed data from the CAPTURE, PURSUIT, and PRISM-PLUS randomized trials, which
studied the effects of the GP IIb/IIIa inhibitors abciximab, eptifibatide, and tirofiban, respectively, in acute coronary
syndrome patients without persistent ST-segment elevation, with a period of study drug infusion before a possible PCI.
During the period of pharmacological treatment, each trial demonstrated a significant reduction in the rate of death or
nonfatal myocardial infarction in patients randomized to the GP IIb/IIIa inhibitor compared with placebo. The 3 trials
combined showed a 2.5% event rate in this period in the GP IIb/IIIa inhibitor group (N56125) versus 3.8% in placebo
(N56171), which implies a 34% relative reduction (P,0.001). During study medication, a PCI was performed in 1358
patients assigned GP IIb/IIIa inhibition and 1396 placebo patients. The event rate during the first 48 hours after PCI was
also significantly lower in the GP IIb/IIIa inhibitor group (4.9% versus 8.0%; 41% reduction; P,0.001). No further
benefit or rebound effect was observed beyond 48 hours after the PCI.
Conclusions—There is conclusive evidence of an early benefit of GP IIb/IIIa inhibitors during medical treatment in
patients with acute coronary syndromes without persistent ST-segment elevation. In addition, in patients subsequently
undergoing PCI, GP IIb/IIIa inhibition protects against myocardial damage associated with the intervention.
(Circulation. 1999;100:2045-2048.)
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Coronary thrombosis is a pivotal event in the pathogenesisof acute coronary syndromes and ischemic complica-
tions resulting from coronary interventions.1 Activation of the
platelet glycoprotein (GP) IIb/IIIa receptor is the final com-
mon pathway in the process leading to platelet aggregation,
coronary thrombus formation, and myocardial ischemia. Ac-
cordingly, inhibitors of platelet GP IIb/IIIa are potent agents
to prevent progression to myocardial infarction (MI) and
death.2 Indeed, in recent randomized clinical trials, GP
IIb/IIIa inhibitors effectively reduced life-threatening compli-
cations in patients with acute coronary syndromes without
ST-segment elevation.3,4 Furthermore, these agents protect
against life-threatening thrombotic complications associated
with percutaneous coronary intervention (PCI).5 The question
arises as to whether these 2 beneficial effects are independent
and additive. To date, 3 clinical trials can contribute to
answering this question (Table 1).3,4,6
CAPTURE studied the effects of abciximab in patients
with unstable angina refractory to conventional medical
therapy.6 A reduction was observed in the rate of death or
nonfatal MI during the 24-hour period of pharmacological
treatment preceding PCI among patients randomized to ab-
ciximab versus placebo (Kaplan-Meier estimates 1.3% versus
2.8%; log-rank P50.032; Figure). The event rate during the
first 48 hours after PCI was significantly lower in abciximab
patients (2.8% versus 5.8% in placebo; P50.009). In the
period starting 48 hours after PCI, only a few events occurred,
with similar rates in both groups.
Observations in PURSUIT confirmed these findings.3
Acute coronary syndrome patients randomized to eptifibatide
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TABLE 1. Characteristics and Management of Patients Enrolled in CAPTURE, PURSUIT, and PRISM-PLUS
CAPTURE (n51265) PURSUIT (n59461) PRISM-PLUS (n51570)
Enrollment criteria Recurrent ischemia under medical
treatment including heparin and
nitrates
Ischemic chest pain within previous 24
h, with ECG or enzymatic evidence of
myocardial ischemia; no persistent
ST-segment elevation
Ischemic chest pain within previous 12
h, with ECG or enzymatic evidence of
myocardial ischemia; no persistent
ST-segment elevation
Mean (SD) age, y 61 (10) 63 (11) 63 (12)
Male, % 73 65 68
Prior MI, % 40 33 42
Prior CABG, % 3 12 14
Prior PTCA, % 13 13 9
Study medication Abciximab (0.25 mg/kg bolus plus 10
mg/min infusion) vs placebo
Eptifibatide (180 mg/kg bolus plus 2.0
mg z kg21 z min21 infusion) vs placebo
Tirofiban (0.4 mg/kg infusion for 30
min followed by 0.1 mg z kg21 z min21
infusion) vs placebo
Duration of study drug infusion 1 h after percutaneous intervention,
which was scheduled at 18–24 h after
randomization
72 h after randomization. In case of a
PCI, for an additional 24 h
48–96 h after randomization. In case
of a PCI, for an additional 12–24 h
Cardiac comedication Aspirin, heparin, nitrates Aspirin, heparin Aspirin, heparin
Further management Percutaneous intervention at 18–24 h
after randomization
At discretion of treating physician Coronary angiography at 48–96 h after
randomization; coronary intervention at
discretion of treating physician
TABLE 2. Mortality and Composite of Death or Nonfatal MI
Placebo GP IIb/IIIa Inhibitor
Odds Ratio (95% CI) Breslow-Dayn
Death,
%
Death or
Nonfatal
MI, % n
Death,
%
Death or
Nonfatal
MI, %
Period: Randomization to randomization124 h or until PCI or surgical coronary intervention (if any)
Patients: All randomized
CAPTURE 635 1 (0.2) 16 (2.5) 630 0 6 (1.0) 0.37 (0.15–0.96)
PURSUIT 4739 13 (0.3) 75 (1.6) 4722 6 (0.1) 50 (1.1) 0.67 (0.46–0.95) 0.502
PRISM-PLUS 797 1 (0.1) 7 (0.9) 773 1 (0.1) 5 (0.6) 0.74 (0.23–2.33)
All 6171 15 (0.2) 98 (1.6) 6125 7 (0.1) 61 (1.0) 0.62 (0.45–0.86)
Period: Randomization to end of study drug infusion or until PCI or surgical coronary intervention (if any)
Patients: All randomized
CAPTURE 635 1 (0.2) 16 (2.5) 630 0 6 (1.0) 0.37 (0.15–0.96)
PURSUIT 4739 40 (0.8) 190 (4.0) 4722 21 (0.4) 137 (2.9) 0.72 (0.57–0.90) 0.201
PRISM-PLUS 797 5 (0.6) 29 (3.6) 773 2 (0.3) 13 (1.7) 0.45 (0.23–0.88)
All 6171 46 (0.7) 235 (3.8) 6125 23 (0.4) 156 (2.5) 0.66 (0.54–0.81)
Period: PCI to PCI148 h
Patients: Undergoing PCI during the scheduled study drug infusion period
CAPTURE 623 3 (0.5) 36 (5.8) 616 2 (0.3) 17 (2.8) 0.46 (0.26–0.83)
PURSUIT 622 7 (1.1) 64 (10.3) 606 4 (0.7) 46 (7.6) 0.72 (0.48–1.07) 0.307
PRISM-PLUS 151 1 (0.7) 12 (7.9) 136 1 (0.7) 4 (2.9) 0.35 (0.11–1.12)
All 1396 11 (0.8) 112 (8.0) 1358 7 (0.5) 67 (4.9) 0.59 (0.44–0.81)
Period: PCI148 h to PCI125 d
Patients: Undergoing PCI during study drug infusion and surviving the first 48 h after PCI
CAPTURE 620 3 (0.5) 7 (1.1) 614 2 (0.3) 4 (0.7) 0.57 (0.17–1.97)
PURSUIT 615 4 (0.7) 10 (1.6) 602 9 (1.5) 14 (2.3) 1.44 (0.64–3.27) 0.199
PRISM-PLUS 150 1 (0.7) 1 (0.7) 135 0 4 (3.0) 4.55 (0.50–41.2)
All 1385 8 (0.6) 18 (1.3) 1351 11 (0.8) 22 (1.6) 1.26 (0.67–2.36)
Breslow-Day indicates Breslow-Day test for homogeneity of odds ratios (P ).
}
}
}
}
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had a 3.2% event rate after the scheduled 72 hours of study
drug infusion, versus 4.4% in placebo (P50.003). There were
also fewer procedure-related events in eptifibatide patients
undergoing a PCI during this period (7.6% versus 10.3% in
placebo; P50.105). In the subsequent postprocedural period
(all patients were off study medication), event rates were low
and similar in both groups.
PRISM-PLUS also confirmed the beneficial effects of GP
IIb/IIIa inhibition before and during PCI.4 Patients assigned
tirofiban had fewer events during initial medical management
(1.8% versus 3.8% in placebo; P50.016) as well as fewer
PCI-related events (2.9% versus 8.0%; P50.062).
There was no evidence of a differential effect of the GP
IIb/IIIa blockers between the trials, in any of the 3 stages,
because all tests for homogeneity of treatment effect were
nonsignificant. Therefore, the separate trial data could be
combined (Figure and Table 2). The 3 trials together demon-
strated a 34% reduction in the composite of death or nonfatal
MI during pharmacological therapy preceding PCI (if any) by
GP IIb/IIIa inhibition [2.5% versus 3.8% in placebo; odds
ratio (95% CI) 0.66 (0.54 to 0.81)] and an additional 41%
reduction in PCI-related events [4.9% versus 8.0%; odds ratio
0.59 (0.44 to 0.81)]. Mortality was low but was still affected
by GP IIb/IIIa inhibition. The incidence of death during
medical therapy was 0.4% among patients randomized to GP
IIb/IIIa inhibition compared with 0.7% among placebo pa-
tients [odds ratio 0.50 (0.30 to 0.83)]. The procedure-related
death rates were 0.5% and 0.8%, respectively [odds ratio 0.65
(0.25 to 1.69)].
Intracoronary stents were used in 10.5% of the CAPTURE
patients. In PURSUIT and PRISM-PLUS, stenting was done
in 50.2% and 20.3% of patients undergoing PCI during study
drug infusion, respectively. Irrespective of treatment assign-
ment, the overall procedure-related event rates were higher
in‘ stented patients (9.3% versus 5.3% in balloon angioplasty;
x2 P,0.001). However, the beneficial effect of GP IIb/IIIa
inhibition was similar in stented and balloon-only patients,
with odds ratios (95% CIs) of 0.61 (0.38 to 0.99) and 0.58
(0.38 to 0.88), respectively (homogeneity test: P50.863).
Late event rates were similar in patients with and without
stents (1.6% versus 1.4%) and were not influenced by the
initial GP IIb/IIIa treatment.
In contrast to CAPTURE, in which all patients were to
undergo PCI, in PURSUIT and PRISM-PLUS the decision to
perform an intervention was at the discretion of the treating
physician. Patients undergoing a PCI in these latter trials were
possibly at higher-than-average risk. Indeed, compared with
CAPTURE, procedure-related event rates in the placebo arms
were higher than expected on the basis of the preprocedural
event rates. These higher event rates, however, did not affect
the benefit of GP IIb/IIIa blockade, because there was no
evidence of a differential effect between the 3 trials. Still, the
observed reduction in procedure-related events by GP IIb/IIIa
treatment in PURSUIT and PRISM-PLUS might have been
biased because of indistinct selection criteria. However, the
incidence of PCI in both treatment arms of these trials was
well balanced, as were the baseline characteristics of the
patients concerned.3,4
The definition of non–PCI-related MI varied among the
trials. In particular, the criteria applied in PURSUIT were
more sensitive, resulting in a relatively high event rate.3 In the
present analysis, similar infarct definitions were applied to all
3 trials (see Figure caption). Supplementary analyses (not
presented) demonstrated that the early beneficial effects were
consistent for different definitions of MI.
In contrast to CAPTURE, the PURSUIT and PRISM-
PLUS studies showed a slightly higher event rate among
patients randomized to GP IIb/IIIa inhibition in the period
starting 48 hours after PCI. This might be a result of
differences in pharmacodynamics between the agents and
between the degree, duration, and specificity of the GP
Kaplan-Meier curves showing cumulative incidence of death or
nonfatal myocardial (re)infarction in patients randomly assigned
to GP IIb/IIIa inhibition (bold lines) or placebo. Data were
derived from CAPTURE, PURSUIT, and PRISM-PLUS.3,4,6 Left,
Event rates during initial period of pharmacological treatment
until moment of a PCI or coronary bypass grafting, if any. Mid-
dle, Event rates among PCI patients during 48-hour period after
procedure. During and shortly after PCI, all patients were on
study medication. Right, Event rates in period starting 48 hours
after PCI, during which all patients were off study medication. At
beginning of each period, event rates were (re)set at 0%. Any
patient still alive contributes to event estimates in each period.
In PURSUIT, procedure-unrelated MI was defined as any eleva-
tion of creatine kinase (CK)-MB above upper limit of normal
(ULN). For consistency with CAPTURE and PRISM-PLUS, in
present analyses only CK or CK-MB elevations .23ULN were
considered to be infarctions during medical therapy. In all 3 tri-
als, procedure-related infarcts were defined by an elevation of
CK or CK-MB .33ULN.
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IIb/IIIa inhibition, although there is no statistical evidence of
a differential late treatment effect between the trials (and thus
between the agents). Additional investigations are needed to
clarify this issue.
In all 3 trials, bleeding complications were more common
in patients treated with GP IIb/IIIa inhibitors than with
placebo.3,4,6 In most cases, however, bleeding was mild and
occurred at the arterial puncture site. The EPILOG trial has
shown that the benefit of GP IIb/IIIa inhibition can be
uncoupled from the risk of hemorrhage in PCI patients by
low-dose, weight-adjusted heparin, adherence to stricter an-
ticoagulation guidelines, and careful vascular access-site
management.7
We conclude that enhanced platelet inhibition with a GP
IIb/IIIa blocker in addition to aspirin and heparin, starting
immediately after admission, is beneficial to patients with
acute coronary syndromes without persistent ST-segment
elevation. In addition, in those undergoing PCI, intensive
platelet inhibition protects against myocardial damage asso-
ciated with the intervention. Thus, to fully explore their
beneficial effects, GP IIb/IIIa inhibitors should be initiated
early after hospital admission and continued until after the
procedure in patients undergoing PCI.
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